Norgine Reinforces Its Commitment to Improving the Detection of Colorectal Cancer
Press Release
By:
Ref: PR Newswire
Published: 03/04/2016
LONDON, March 4, 2016 /PRNewswire/ -- Norgine B.V. today announces that it is supporting the March 2016 European Colorectal Cancer awareness campaign. Colorectal cancer is the second most common cause of cancer-related mortality in the world[1], with nearly 1.4 million new cases diagnosed worldwide and 412,000 people in Europe. [2],[3]
As a leader in bowel cleansing and colonoscopy, Norgine has been collaborating with key European patient organisations in order to increase the detection of colorectal cancer and to help improve patients' quality of life. Norgine is a patient centric company and is supporting key organisations such as;
• Alianza para la prevención del Cáncer de colon, Spain
• Asociación de pacientes con síndrome de Lynch, Spain
• Beating Bowel Cancer, UK
• Bowel Cancer UK
• Conseil National Professionnel d'Hépato-Gastroentérologie, France
• Deutschland gegen Darmkrebs, Germany
• Dutch Digestive Foundation, The Netherlands
• Felix Burda Foundation, Germany
• Selbsthilfgruppe Darmkrebs, Austria
• Spanish Digestive Society Foundation, Spain
• Stiftung LebensBlicke, Germany
• Stop Darmkanker, Belgium
Over the years, Norgine has strengthened its colon cancer prevention and detection portfolio to ensure quality in colonoscopy and ultimately enhance health outcomes for patients.
Norigne's bowel cleansing and colonoscopy portfolio includes KLEAN-PREP®, MOVIPREP® and ENDOCUFF VISION®.
Click here to view the full list of all organisations to whom Norgine provides support.
Notes to Editors:
About Norgine
Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2015, Norgine's total revenue was EUR 317 million and the company employs over 1,000 people.
Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.
For more information, please visit http://www.norgine.com
NORGINE and the sail logo are trademarks of the Norgine group of companies.
References
[1] Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403
[2] Colorectal Cancer Statistics, World Cancer Research Fund International, http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/colorectal-cancer-statistics [Accessed 3 March 2016]
[3] Zavoral M et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009;15(47):5907-5915
SOURCE Norgine B.V.
As a leader in bowel cleansing and colonoscopy, Norgine has been collaborating with key European patient organisations in order to increase the detection of colorectal cancer and to help improve patients' quality of life. Norgine is a patient centric company and is supporting key organisations such as;
• Alianza para la prevención del Cáncer de colon, Spain
• Asociación de pacientes con síndrome de Lynch, Spain
• Beating Bowel Cancer, UK
• Bowel Cancer UK
• Conseil National Professionnel d'Hépato-Gastroentérologie, France
• Deutschland gegen Darmkrebs, Germany
• Dutch Digestive Foundation, The Netherlands
• Felix Burda Foundation, Germany
• Selbsthilfgruppe Darmkrebs, Austria
• Spanish Digestive Society Foundation, Spain
• Stiftung LebensBlicke, Germany
• Stop Darmkanker, Belgium
Over the years, Norgine has strengthened its colon cancer prevention and detection portfolio to ensure quality in colonoscopy and ultimately enhance health outcomes for patients.
Norigne's bowel cleansing and colonoscopy portfolio includes KLEAN-PREP®, MOVIPREP® and ENDOCUFF VISION®.
Click here to view the full list of all organisations to whom Norgine provides support.
Notes to Editors:
About Norgine
Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2015, Norgine's total revenue was EUR 317 million and the company employs over 1,000 people.
Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.
For more information, please visit http://www.norgine.com
NORGINE and the sail logo are trademarks of the Norgine group of companies.
References
[1] Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403
[2] Colorectal Cancer Statistics, World Cancer Research Fund International, http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/colorectal-cancer-statistics [Accessed 3 March 2016]
[3] Zavoral M et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009;15(47):5907-5915
SOURCE Norgine B.V.